In making its decision, the judging panel, consisting of leaders in venture capital and biotechnology, considered, among other attributes, the strength of Immusoft’s intellectual property, its ability to disrupt the current standard-of-care, as well as its commercialization strategy and expected value creation for shareholders.
Bonti Announces Close of $15.5 Million Series C Funding and Appointment of David Ramsay as Chief Financial Officer
Latest Financing to Enable Continued Clinical Development of Lead Product EB-001 to Treat Musculoskeletal Pain
The funding is first part of the company’s ongoing Series B round.
Fauad Hasan, CEO and Co-founder, to Spotlight the Company in San Francisco.
The company will present their latest scientific work in advanced quantitative image analysis in renal cell carcinoma (RCC) in collaboration with the Peter MacCallum Cancer Center, Melbourne, Australia.